News Scientific study suggests that mesoporous silica particles (MSPs) interact with the lipid digestion and absorption pathways to reduce calorific uptake Stockholm, March 21st, 2022: Sigrid Therapeutics today announced the publication of a multifaceted, scientific study…SanaMarch 21, 2022
News Sigrid Therapeutics granted European patent covering the use of porous SiPore® silica particles as pharmaceutical or dietary active ingredients Stockholm, Sweden March 7, 2022. Sigrid Therapeutics, a Swedish healthtech company specializing in the prevention…SanaMarch 7, 2022
News Sigrid Therapeutics’ Co-founder & CEO Sana Alajmovic named Sweden’s Female Founder of the Year 2021 SanaNovember 30, 2021
News Sigrid Therapeutics tar in 72 Mkr i nytt kapital Kapitalet kommer från amerikanska, irländska och svenska investerare för att finansiera klinisk studie och internationell…SanaNovember 10, 2021
News Sigrid Therapeutics raises funding of $8.4M This financing round was raised from US, Irish and Swedish investors alongside a large-scale industrial…SanaNovember 10, 2021
News Unique Swedish concept for two of the world’s biggest health challenges closer to breakthrough Swedish Sigrid Therapeutics, which has developed a unique concept to prevent two of the world's…SanaNovember 8, 2021
News Sigrid Profiled in SvD, Sweden’s Largest Daily Magazine We are happy to have been profiled in SvD, Sweden's largest daily magazine. Read more…SanaNovember 3, 2021
News Former President of Eli Lilly Research Labs and Head of R&D Dr. Jan Lundberg invests in Sigrid Therapeutics and joins the Company’s Scientific Advisory Board Breakthrough SiPore15TM silica particle-based diabetes and obesity treatment on track for commercial material scale up…Liu MingJune 2, 2020
News Sana Alajmovic: ”Vi måste tala om de stora visionerna – bygga nästa Astra” Life Science Sweden BenMay 12, 2020